Mintz advised 5 Prime Sciences, a biotechnology data analytics company focused on using human genetics to accelerate drug development, in a strategic collaboration with Eli Lilly and Company dedicated to accelerating target discovery and early development in the field of cardio-metabolic diseases. The collaboration integrates Lilly’s leadership in cardio-metabolic disease therapies with 5 Prime Sciences’ cutting-edge expertise in discovery and validation of drug targets using human genetics, proteomics, and metabolomics.

Under the terms of the agreement, 5 Prime Sciences will deploy its state-of-the-art human genetics, multi-omics and AI technologies to identify and validate potential drug targets in cardio-metabolic diseases, including diabetes, obesity, and related conditions. Additional information about the collaboration is available here.

The Mintz deal team was led by Partner Cheryl Reicin and Associate Adam Falconi.